DNA vaccine

Applied DNA Biotherapeutics Subsidiary LineaRx and EvviVax Publish Additional Positive Animal Proof-of-Concept Data Supporting LinearDNA™ Platform as a Unique Approach to Veterinary DNA Vaccine Development

Retrieved on: 
Monday, July 25, 2022

The manuscript, authored by LineaRx, the Companys majority-owned biotherapeutics subsidiary, and LineaRxs development partner, EvviVax, S.R.L., further establishes the utility of the LinearDNA ("linDNA) platform as a large-scale enzymatic production approach to prophylactic and therapeutic veterinary vaccine applications.

Key Points: 
  • The manuscript, authored by LineaRx, the Companys majority-owned biotherapeutics subsidiary, and LineaRxs development partner, EvviVax, S.R.L., further establishes the utility of the LinearDNA ("linDNA) platform as a large-scale enzymatic production approach to prophylactic and therapeutic veterinary vaccine applications.
  • It details positive data showing safety and immunogenicity of a linDNA vaccine candidate against SARS-CoV-2 in a cohort of family-owned cats.
  • Separately, LineaRx announced the successful expression in vitro of its linDNA SARS-CoV-2 vaccine candidate encapsulated within lipid nanoparticles (LNP).
  • Evvivax pursues the discovery and development of innovative Therapeutic Veterinary Cancer Vaccines based on proprietary viral vectors and DNA platform technologies.

Evaxion Biotech Reports Preclinical Proof of Concept Data for Evaxion’s AI-powered Vaccine Platform RAVEN for the Design of a Next Generation SARS-CoV-2 Vaccine

Retrieved on: 
Thursday, June 3, 2021

The AICoV program aims to potentially develop the next generation of corona virus vaccines, utilizing RAVEN, Evaxions AI powered vaccine design platform, along with Evaxions proprietary Antigen Presenting Cell (APC) targeting DNA vaccine technology and novel manufacturing approaches.

Key Points: 
  • The AICoV program aims to potentially develop the next generation of corona virus vaccines, utilizing RAVEN, Evaxions AI powered vaccine design platform, along with Evaxions proprietary Antigen Presenting Cell (APC) targeting DNA vaccine technology and novel manufacturing approaches.
  • The RAVEN platform, an integral part of Evaxions AICoV program, combines advanced algorithms from Evaxions proprietary AI-immunology Core technology to identify optimal T and B cell antigen targets for the development of novel viral vaccines.
  • Early data demonstrate that RAVEN identifies novel immunogenic T cell epitopes outside the spike protein, showing RAVENs potential to rapidly support the design of novel SARS-COV-2 vaccines against current and future variants.
  • In addition, Evaxion is advancing a portfolio of vaccines to prevent bacterial and viral infections currently in preclinical development.

Global Vaccine Adjuvants Market to 2025 - Increasing Use of Recombinant Subunit and Synthetic Vaccines - ResearchAndMarkets.com

Retrieved on: 
Wednesday, February 10, 2021

The propelling factors for the growth of the vaccine adjuvants market include the unmet needs for vaccines against certain diseases, expanding government recommendations for immunizations, technological innovations, and increasing use of recombinant subunit and synthetic vaccines.

Key Points: 
  • The propelling factors for the growth of the vaccine adjuvants market include the unmet needs for vaccines against certain diseases, expanding government recommendations for immunizations, technological innovations, and increasing use of recombinant subunit and synthetic vaccines.
  • The adjuvant market is gaining a boost from the increasing use of recombinant subunit vaccines.
  • Over the coming years, more developments are expected to take place, increasing the need for adjuvants.
  • Thus, the negative impacts of toxicity of adjuvants on vaccine manufacturing cost and safety profiles of vaccines are hindering the growth of the market.

Hanmi presents solution package strategy to potentially overcome COVID-19 at the 39th JP Morgan Healthcare Conference

Retrieved on: 
Tuesday, January 12, 2021

Pyeongtaek Bio Plant possesses a GMP facility where bulk drug substances of mRNA and pDNA vaccines can be produced.

Key Points: 
  • Pyeongtaek Bio Plant possesses a GMP facility where bulk drug substances of mRNA and pDNA vaccines can be produced.
  • Hanmi Pharmaceutical Co., Ltd. is developing a full package to handle the prevention, diagnosis, and treatment of COVID-19.
  • Hanmi recently released 'Hanmi Cold-Mask nasal spray', whose main ingredient is -carrageenan (lambda-carrageenan) extract that can prevent respiratory viral infection.
  • Hanmi Bio Plant has two production buildings (Production Buildings 1 and 2) at the site with an area of 51,498 m2.

Hanmi presents solution package strategy to potentially overcome COVID-19 at the 39th JP Morgan Healthcare Conference

Retrieved on: 
Tuesday, January 12, 2021

Pyeongtaek Bio Plant possesses a GMP facility where bulk drug substances of mRNA and pDNA vaccines can be produced.

Key Points: 
  • Pyeongtaek Bio Plant possesses a GMP facility where bulk drug substances of mRNA and pDNA vaccines can be produced.
  • Hanmi Pharmaceutical Co., Ltd. is developing a full package to handle the prevention, diagnosis, and treatment of COVID-19.
  • Hanmi recently released 'Hanmi Cold-Mask nasal spray', whose main ingredient is -carrageenan (lambda-carrageenan) extract that can prevent respiratory viral infection.
  • Hanmi Bio Plant has two production buildings (Production Buildings 1 and 2) at the site with an area of 51,498 m2.